カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

潰瘍性大腸炎治療薬の世界市場2022：経口型、注射型

◆英語タイトル：Global Drug for Ulcerative Colitis Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが発行した調査報告書（GIR22DC3786）◆商品コード：GIR22DC3786
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2023年1月（※2025年版があります。お問い合わせください。）
◆ページ数：106
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥501,120見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥751,680見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,002,240見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

世界の潰瘍性大腸炎治療薬市場レポートは、グローバル市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
Global Info Research社の最新のリサーチによると、世界の潰瘍性大腸炎治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

潰瘍性大腸炎治療薬市場はタイプとアプリケーションによって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメントは次をカバーします。
・経口型、注射型

アプリケーション別セグメントは次のように区分されます。
・病院、ドラッグストア

世界の潰瘍性大腸炎治療薬市場の主要な市場プレーヤーは以下のとおりです。
・Johnson & Johnson.、AbbVie、Takeda Pharmaceuticals、Roche、Warner Chilcott、Salix Pharmaceuticals/Santarus、Takeda、Ferring Pharmaceuticals、Pfizer、InDeX Pharmaceuticals

地域別セグメントは次の地域・国をカバーします。
・北米（アメリカ、カナダ、メキシコ）
・欧州（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南米（ブラジル、アルゼンチン、コロンビア）
・中東/アフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査資料の内容は計15章あります。
・第1章では、潰瘍性大腸炎治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な潰瘍性大腸炎治療薬メーカーの企業概要、2019年～2022年までの潰瘍性大腸炎治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な潰瘍性大腸炎治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別潰瘍性大腸炎治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの潰瘍性大腸炎治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での潰瘍性大腸炎治療薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および潰瘍性大腸炎治療薬の産業チェーンを掲載しています。
・第13、14、15章では、潰瘍性大腸炎治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
– 潰瘍性大腸炎治療薬の概要
– 種類別分析（2017年vs2021年vs2028年）：経口型、注射型
– 用途別分析（2017年vs2021年vs2028年）：病院、ドラッグストア
– 世界の潰瘍性大腸炎治療薬市場規模・予測
– 世界の潰瘍性大腸炎治療薬生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Johnson & Johnson.、AbbVie、Takeda Pharmaceuticals、Roche、Warner Chilcott、Salix Pharmaceuticals/Santarus、Takeda、Ferring Pharmaceuticals、Pfizer、InDeX Pharmaceuticals
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：経口型、注射型
・用途別分析2017年-2028年：病院、ドラッグストア
・潰瘍性大腸炎治療薬の北米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・潰瘍性大腸炎治療薬のヨーロッパ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・潰瘍性大腸炎治療薬のアジア市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・潰瘍性大腸炎治療薬の南米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・潰瘍性大腸炎治療薬の中東・アフリカ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

❖ レポートの目次 ❖

1 Market Overview
1.1 Drug for Ulcerative Colitis Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Drug for Ulcerative Colitis Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Oral
1.2.3 Injection
1.3 Market Analysis by Application
1.3.1 Overview: Global Drug for Ulcerative Colitis Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Drugs Stores
1.4 Global Drug for Ulcerative Colitis Market Size & Forecast
1.4.1 Global Drug for Ulcerative Colitis Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Drug for Ulcerative Colitis Sales in Volume (2017-2028)
1.4.3 Global Drug for Ulcerative Colitis Price (2017-2028)
1.5 Global Drug for Ulcerative Colitis Production Capacity Analysis
1.5.1 Global Drug for Ulcerative Colitis Total Production Capacity (2017-2028)
1.5.2 Global Drug for Ulcerative Colitis Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Drug for Ulcerative Colitis Market Drivers
1.6.2 Drug for Ulcerative Colitis Market Restraints
1.6.3 Drug for Ulcerative Colitis Trends Analysis
2 Manufacturers Profiles
2.1 Johnson & Johnson.
2.1.1 Johnson & Johnson. Details
2.1.2 Johnson & Johnson. Major Business
2.1.3 Johnson & Johnson. Drug for Ulcerative Colitis Product and Services
2.1.4 Johnson & Johnson. Drug for Ulcerative Colitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 AbbVie
2.2.1 AbbVie Details
2.2.2 AbbVie Major Business
2.2.3 AbbVie Drug for Ulcerative Colitis Product and Services
2.2.4 AbbVie Drug for Ulcerative Colitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Takeda Pharmaceuticals
2.3.1 Takeda Pharmaceuticals Details
2.3.2 Takeda Pharmaceuticals Major Business
2.3.3 Takeda Pharmaceuticals Drug for Ulcerative Colitis Product and Services
2.3.4 Takeda Pharmaceuticals Drug for Ulcerative Colitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche Drug for Ulcerative Colitis Product and Services
2.4.4 Roche Drug for Ulcerative Colitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Warner Chilcott
2.5.1 Warner Chilcott Details
2.5.2 Warner Chilcott Major Business
2.5.3 Warner Chilcott Drug for Ulcerative Colitis Product and Services
2.5.4 Warner Chilcott Drug for Ulcerative Colitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Salix Pharmaceuticals/Santarus
2.6.1 Salix Pharmaceuticals/Santarus Details
2.6.2 Salix Pharmaceuticals/Santarus Major Business
2.6.3 Salix Pharmaceuticals/Santarus Drug for Ulcerative Colitis Product and Services
2.6.4 Salix Pharmaceuticals/Santarus Drug for Ulcerative Colitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Takeda
2.7.1 Takeda Details
2.7.2 Takeda Major Business
2.7.3 Takeda Drug for Ulcerative Colitis Product and Services
2.7.4 Takeda Drug for Ulcerative Colitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Ferring Pharmaceuticals
2.8.1 Ferring Pharmaceuticals Details
2.8.2 Ferring Pharmaceuticals Major Business
2.8.3 Ferring Pharmaceuticals Drug for Ulcerative Colitis Product and Services
2.8.4 Ferring Pharmaceuticals Drug for Ulcerative Colitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Drug for Ulcerative Colitis Product and Services
2.9.4 Pfizer Drug for Ulcerative Colitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 InDeX Pharmaceuticals
2.10.1 InDeX Pharmaceuticals Details
2.10.2 InDeX Pharmaceuticals Major Business
2.10.3 InDeX Pharmaceuticals Drug for Ulcerative Colitis Product and Services
2.10.4 InDeX Pharmaceuticals Drug for Ulcerative Colitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Drug for Ulcerative Colitis Breakdown Data by Manufacturer
3.1 Global Drug for Ulcerative Colitis Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Drug for Ulcerative Colitis Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Drug for Ulcerative Colitis
3.4 Market Concentration Rate
3.4.1 Top 3 Drug for Ulcerative Colitis Manufacturer Market Share in 2021
3.4.2 Top 6 Drug for Ulcerative Colitis Manufacturer Market Share in 2021
3.5 Global Drug for Ulcerative Colitis Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Drug for Ulcerative Colitis Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Drug for Ulcerative Colitis Market Size by Region
4.1.1 Global Drug for Ulcerative Colitis Sales in Volume by Region (2017-2028)
4.1.2 Global Drug for Ulcerative Colitis Revenue by Region (2017-2028)
4.2 North America Drug for Ulcerative Colitis Revenue (2017-2028)
4.3 Europe Drug for Ulcerative Colitis Revenue (2017-2028)
4.4 Asia-Pacific Drug for Ulcerative Colitis Revenue (2017-2028)
4.5 South America Drug for Ulcerative Colitis Revenue (2017-2028)
4.6 Middle East and Africa Drug for Ulcerative Colitis Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Drug for Ulcerative Colitis Sales in Volume by Type (2017-2028)
5.2 Global Drug for Ulcerative Colitis Revenue by Type (2017-2028)
5.3 Global Drug for Ulcerative Colitis Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Drug for Ulcerative Colitis Sales in Volume by Application (2017-2028)
6.2 Global Drug for Ulcerative Colitis Revenue by Application (2017-2028)
6.3 Global Drug for Ulcerative Colitis Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Drug for Ulcerative Colitis Sales by Type (2017-2028)
7.2 North America Drug for Ulcerative Colitis Sales by Application (2017-2028)
7.3 North America Drug for Ulcerative Colitis Market Size by Country
7.3.1 North America Drug for Ulcerative Colitis Sales in Volume by Country (2017-2028)
7.3.2 North America Drug for Ulcerative Colitis Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Drug for Ulcerative Colitis Sales by Type (2017-2028)
8.2 Europe Drug for Ulcerative Colitis Sales by Application (2017-2028)
8.3 Europe Drug for Ulcerative Colitis Market Size by Country
8.3.1 Europe Drug for Ulcerative Colitis Sales in Volume by Country (2017-2028)
8.3.2 Europe Drug for Ulcerative Colitis Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Drug for Ulcerative Colitis Sales by Type (2017-2028)
9.2 Asia-Pacific Drug for Ulcerative Colitis Sales by Application (2017-2028)
9.3 Asia-Pacific Drug for Ulcerative Colitis Market Size by Region
9.3.1 Asia-Pacific Drug for Ulcerative Colitis Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Drug for Ulcerative Colitis Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Drug for Ulcerative Colitis Sales by Type (2017-2028)
10.2 South America Drug for Ulcerative Colitis Sales by Application (2017-2028)
10.3 South America Drug for Ulcerative Colitis Market Size by Country
10.3.1 South America Drug for Ulcerative Colitis Sales in Volume by Country (2017-2028)
10.3.2 South America Drug for Ulcerative Colitis Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Drug for Ulcerative Colitis Sales by Type (2017-2028)
11.2 Middle East & Africa Drug for Ulcerative Colitis Sales by Application (2017-2028)
11.3 Middle East & Africa Drug for Ulcerative Colitis Market Size by Country
11.3.1 Middle East & Africa Drug for Ulcerative Colitis Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Drug for Ulcerative Colitis Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Drug for Ulcerative Colitis and Key Manufacturers
12.2 Manufacturing Costs Percentage of Drug for Ulcerative Colitis
12.3 Drug for Ulcerative Colitis Production Process
12.4 Drug for Ulcerative Colitis Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Drug for Ulcerative Colitis Typical Distributors
13.3 Drug for Ulcerative Colitis Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Drug for Ulcerative Colitis Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Drug for Ulcerative Colitis Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Johnson & Johnson. Basic Information, Manufacturing Base and Competitors
Table 4. Johnson & Johnson. Major Business
Table 5. Johnson & Johnson. Drug for Ulcerative Colitis Product and Services
Table 6. Johnson & Johnson. Drug for Ulcerative Colitis Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. AbbVie Basic Information, Manufacturing Base and Competitors
Table 8. AbbVie Major Business
Table 9. AbbVie Drug for Ulcerative Colitis Product and Services
Table 10. AbbVie Drug for Ulcerative Colitis Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 12. Takeda Pharmaceuticals Major Business
Table 13. Takeda Pharmaceuticals Drug for Ulcerative Colitis Product and Services
Table 14. Takeda Pharmaceuticals Drug for Ulcerative Colitis Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Roche Basic Information, Manufacturing Base and Competitors
Table 16. Roche Major Business
Table 17. Roche Drug for Ulcerative Colitis Product and Services
Table 18. Roche Drug for Ulcerative Colitis Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Warner Chilcott Basic Information, Manufacturing Base and Competitors
Table 20. Warner Chilcott Major Business
Table 21. Warner Chilcott Drug for Ulcerative Colitis Product and Services
Table 22. Warner Chilcott Drug for Ulcerative Colitis Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Salix Pharmaceuticals/Santarus Basic Information, Manufacturing Base and Competitors
Table 24. Salix Pharmaceuticals/Santarus Major Business
Table 25. Salix Pharmaceuticals/Santarus Drug for Ulcerative Colitis Product and Services
Table 26. Salix Pharmaceuticals/Santarus Drug for Ulcerative Colitis Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Takeda Basic Information, Manufacturing Base and Competitors
Table 28. Takeda Major Business
Table 29. Takeda Drug for Ulcerative Colitis Product and Services
Table 30. Takeda Drug for Ulcerative Colitis Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Ferring Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 32. Ferring Pharmaceuticals Major Business
Table 33. Ferring Pharmaceuticals Drug for Ulcerative Colitis Product and Services
Table 34. Ferring Pharmaceuticals Drug for Ulcerative Colitis Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Pfizer Basic Information, Manufacturing Base and Competitors
Table 36. Pfizer Major Business
Table 37. Pfizer Drug for Ulcerative Colitis Product and Services
Table 38. Pfizer Drug for Ulcerative Colitis Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. InDeX Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 40. InDeX Pharmaceuticals Major Business
Table 41. InDeX Pharmaceuticals Drug for Ulcerative Colitis Product and Services
Table 42. InDeX Pharmaceuticals Drug for Ulcerative Colitis Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Global Drug for Ulcerative Colitis Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 44. Global Drug for Ulcerative Colitis Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 45. Market Position of Manufacturers in Drug for Ulcerative Colitis, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 46. Global Drug for Ulcerative Colitis Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Drug for Ulcerative Colitis Production Site of Key Manufacturer
Table 48. Drug for Ulcerative Colitis New Entrant and Capacity Expansion Plans
Table 49. Drug for Ulcerative Colitis Mergers & Acquisitions in the Past Five Years
Table 50. Global Drug for Ulcerative Colitis Sales by Region (2017-2022) & (K Units)
Table 51. Global Drug for Ulcerative Colitis Sales by Region (2023-2028) & (K Units)
Table 52. Global Drug for Ulcerative Colitis Revenue by Region (2017-2022) & (USD Million)
Table 53. Global Drug for Ulcerative Colitis Revenue by Region (2023-2028) & (USD Million)
Table 54. Global Drug for Ulcerative Colitis Sales by Type (2017-2022) & (K Units)
Table 55. Global Drug for Ulcerative Colitis Sales by Type (2023-2028) & (K Units)
Table 56. Global Drug for Ulcerative Colitis Revenue by Type (2017-2022) & (USD Million)
Table 57. Global Drug for Ulcerative Colitis Revenue by Type (2023-2028) & (USD Million)
Table 58. Global Drug for Ulcerative Colitis Price by Type (2017-2022) & (USD/Unit)
Table 59. Global Drug for Ulcerative Colitis Price by Type (2023-2028) & (USD/Unit)
Table 60. Global Drug for Ulcerative Colitis Sales by Application (2017-2022) & (K Units)
Table 61. Global Drug for Ulcerative Colitis Sales by Application (2023-2028) & (K Units)
Table 62. Global Drug for Ulcerative Colitis Revenue by Application (2017-2022) & (USD Million)
Table 63. Global Drug for Ulcerative Colitis Revenue by Application (2023-2028) & (USD Million)
Table 64. Global Drug for Ulcerative Colitis Price by Application (2017-2022) & (USD/Unit)
Table 65. Global Drug for Ulcerative Colitis Price by Application (2023-2028) & (USD/Unit)
Table 66. North America Drug for Ulcerative Colitis Sales by Country (2017-2022) & (K Units)
Table 67. North America Drug for Ulcerative Colitis Sales by Country (2023-2028) & (K Units)
Table 68. North America Drug for Ulcerative Colitis Revenue by Country (2017-2022) & (USD Million)
Table 69. North America Drug for Ulcerative Colitis Revenue by Country (2023-2028) & (USD Million)
Table 70. North America Drug for Ulcerative Colitis Sales by Type (2017-2022) & (K Units)
Table 71. North America Drug for Ulcerative Colitis Sales by Type (2023-2028) & (K Units)
Table 72. North America Drug for Ulcerative Colitis Sales by Application (2017-2022) & (K Units)
Table 73. North America Drug for Ulcerative Colitis Sales by Application (2023-2028) & (K Units)
Table 74. Europe Drug for Ulcerative Colitis Sales by Country (2017-2022) & (K Units)
Table 75. Europe Drug for Ulcerative Colitis Sales by Country (2023-2028) & (K Units)
Table 76. Europe Drug for Ulcerative Colitis Revenue by Country (2017-2022) & (USD Million)
Table 77. Europe Drug for Ulcerative Colitis Revenue by Country (2023-2028) & (USD Million)
Table 78. Europe Drug for Ulcerative Colitis Sales by Type (2017-2022) & (K Units)
Table 79. Europe Drug for Ulcerative Colitis Sales by Type (2023-2028) & (K Units)
Table 80. Europe Drug for Ulcerative Colitis Sales by Application (2017-2022) & (K Units)
Table 81. Europe Drug for Ulcerative Colitis Sales by Application (2023-2028) & (K Units)
Table 82. Asia-Pacific Drug for Ulcerative Colitis Sales by Region (2017-2022) & (K Units)
Table 83. Asia-Pacific Drug for Ulcerative Colitis Sales by Region (2023-2028) & (K Units)
Table 84. Asia-Pacific Drug for Ulcerative Colitis Revenue by Region (2017-2022) & (USD Million)
Table 85. Asia-Pacific Drug for Ulcerative Colitis Revenue by Region (2023-2028) & (USD Million)
Table 86. Asia-Pacific Drug for Ulcerative Colitis Sales by Type (2017-2022) & (K Units)
Table 87. Asia-Pacific Drug for Ulcerative Colitis Sales by Type (2023-2028) & (K Units)
Table 88. Asia-Pacific Drug for Ulcerative Colitis Sales by Application (2017-2022) & (K Units)
Table 89. Asia-Pacific Drug for Ulcerative Colitis Sales by Application (2023-2028) & (K Units)
Table 90. South America Drug for Ulcerative Colitis Sales by Country (2017-2022) & (K Units)
Table 91. South America Drug for Ulcerative Colitis Sales by Country (2023-2028) & (K Units)
Table 92. South America Drug for Ulcerative Colitis Revenue by Country (2017-2022) & (USD Million)
Table 93. South America Drug for Ulcerative Colitis Revenue by Country (2023-2028) & (USD Million)
Table 94. South America Drug for Ulcerative Colitis Sales by Type (2017-2022) & (K Units)
Table 95. South America Drug for Ulcerative Colitis Sales by Type (2023-2028) & (K Units)
Table 96. South America Drug for Ulcerative Colitis Sales by Application (2017-2022) & (K Units)
Table 97. South America Drug for Ulcerative Colitis Sales by Application (2023-2028) & (K Units)
Table 98. Middle East & Africa Drug for Ulcerative Colitis Sales by Region (2017-2022) & (K Units)
Table 99. Middle East & Africa Drug for Ulcerative Colitis Sales by Region (2023-2028) & (K Units)
Table 100. Middle East & Africa Drug for Ulcerative Colitis Revenue by Region (2017-2022) & (USD Million)
Table 101. Middle East & Africa Drug for Ulcerative Colitis Revenue by Region (2023-2028) & (USD Million)
Table 102. Middle East & Africa Drug for Ulcerative Colitis Sales by Type (2017-2022) & (K Units)
Table 103. Middle East & Africa Drug for Ulcerative Colitis Sales by Type (2023-2028) & (K Units)
Table 104. Middle East & Africa Drug for Ulcerative Colitis Sales by Application (2017-2022) & (K Units)
Table 105. Middle East & Africa Drug for Ulcerative Colitis Sales by Application (2023-2028) & (K Units)
Table 106. Drug for Ulcerative Colitis Raw Material
Table 107. Key Manufacturers of Drug for Ulcerative Colitis Raw Materials
Table 108. Direct Channel Pros & Cons
Table 109. Indirect Channel Pros & Cons
Table 110. Drug for Ulcerative Colitis Typical Distributors
Table 111. Drug for Ulcerative Colitis Typical Customers
List of Figures
Figure 1. Drug for Ulcerative Colitis Picture
Figure 2. Global Drug for Ulcerative Colitis Revenue Market Share by Type in 2021
Figure 3. Oral
Figure 4. Injection
Figure 5. Global Drug for Ulcerative Colitis Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Drugs Stores
Figure 8. Global Drug for Ulcerative Colitis Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Drug for Ulcerative Colitis Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Drug for Ulcerative Colitis Sales (2017-2028) & (K Units)
Figure 11. Global Drug for Ulcerative Colitis Price (2017-2028) & (USD/Unit)
Figure 12. Global Drug for Ulcerative Colitis Production Capacity (2017-2028) & (K Units)
Figure 13. Global Drug for Ulcerative Colitis Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Drug for Ulcerative Colitis Market Drivers
Figure 15. Drug for Ulcerative Colitis Market Restraints
Figure 16. Drug for Ulcerative Colitis Market Trends
Figure 17. Global Drug for Ulcerative Colitis Sales Market Share by Manufacturer in 2021
Figure 18. Global Drug for Ulcerative Colitis Revenue Market Share by Manufacturer in 2021
Figure 19. Drug for Ulcerative Colitis Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Drug for Ulcerative Colitis Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Drug for Ulcerative Colitis Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Drug for Ulcerative Colitis Sales Market Share by Region (2017-2028)
Figure 23. Global Drug for Ulcerative Colitis Revenue Market Share by Region (2017-2028)
Figure 24. North America Drug for Ulcerative Colitis Revenue (2017-2028) & (USD Million)
Figure 25. Europe Drug for Ulcerative Colitis Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Drug for Ulcerative Colitis Revenue (2017-2028) & (USD Million)
Figure 27. South America Drug for Ulcerative Colitis Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Drug for Ulcerative Colitis Revenue (2017-2028) & (USD Million)
Figure 29. Global Drug for Ulcerative Colitis Sales Market Share by Type (2017-2028)
Figure 30. Global Drug for Ulcerative Colitis Revenue Market Share by Type (2017-2028)
Figure 31. Global Drug for Ulcerative Colitis Price by Type (2017-2028) & (USD/Unit)
Figure 32. Global Drug for Ulcerative Colitis Sales Market Share by Application (2017-2028)
Figure 33. Global Drug for Ulcerative Colitis Revenue Market Share by Application (2017-2028)
Figure 34. Global Drug for Ulcerative Colitis Price by Application (2017-2028) & (USD/Unit)
Figure 35. North America Drug for Ulcerative Colitis Sales Market Share by Type (2017-2028)
Figure 36. North America Drug for Ulcerative Colitis Sales Market Share by Application (2017-2028)
Figure 37. North America Drug for Ulcerative Colitis Sales Market Share by Country (2017-2028)
Figure 38. North America Drug for Ulcerative Colitis Revenue Market Share by Country (2017-2028)
Figure 39. United States Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Drug for Ulcerative Colitis Sales Market Share by Type (2017-2028)
Figure 43. Europe Drug for Ulcerative Colitis Sales Market Share by Application (2017-2028)
Figure 44. Europe Drug for Ulcerative Colitis Sales Market Share by Country (2017-2028)
Figure 45. Europe Drug for Ulcerative Colitis Revenue Market Share by Country (2017-2028)
Figure 46. Germany Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Drug for Ulcerative Colitis Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Drug for Ulcerative Colitis Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Drug for Ulcerative Colitis Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Drug for Ulcerative Colitis Revenue Market Share by Region (2017-2028)
Figure 55. China Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Drug for Ulcerative Colitis Sales Market Share by Type (2017-2028)
Figure 62. South America Drug for Ulcerative Colitis Sales Market Share by Application (2017-2028)
Figure 63. South America Drug for Ulcerative Colitis Sales Market Share by Country (2017-2028)
Figure 64. South America Drug for Ulcerative Colitis Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Drug for Ulcerative Colitis Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Drug for Ulcerative Colitis Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Drug for Ulcerative Colitis Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Drug for Ulcerative Colitis Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Drug for Ulcerative Colitis Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Drug for Ulcerative Colitis in 2021
Figure 76. Manufacturing Process Analysis of Drug for Ulcerative Colitis
Figure 77. Drug for Ulcerative Colitis Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source

※参考情報

潰瘍性大腸炎（UC）は、慢性的な炎症を引き起こす自己免疫疾患であり、主に大腸と直腸に影響を及ぼします。この病気は、腹痛、下痢、血便などの症状を伴い、患者の生活の質に大きな影響を与える可能性があります。そのため、潰瘍性大腸炎の治療においては、薬物療法が非常に重要な役割を果たしています。ここでは、潰瘍性大腸炎の治療薬の概念について詳しく解説いたします。

まず、潰瘍性大腸炎治療薬の定義についてお話しします。これらの薬は、炎症を抑えることに重点を置いたもので、疾患の活動性の低下や寛解を目指して用いられます。治療薬は、抗炎症作用を持つもの、免疫抑制作用があるもの、生物学的製剤など、さまざまな種類があります。

潰瘍性大腸炎の治療薬は、主に以下のような特徴を持っています。まず、効果の発現に時間がかかるものが多いという点です。例えば、5-アミノサリチル酸（5-ASA）系薬や免疫抑制剤は、一般的に数週間から数ヶ月かかって効果が現れるため、治療開始からの継続が重要です。また、これらの薬は慢性的な疾患であるため、長期間にわたって使用されることが一般的であり、そのため副作用の管理も重要なポイントとなります。

治療薬の種類については、主に以下のカテゴリに分けることができます。まず最初に5-アミノサリチル酸（5-ASA）系薬があります。これは、抗炎症作用を持ち、大腸の粘膜に直接作用して炎症を抑えるものです。例えば、メサラジンやサリチル酸メチルが含まれます。これらは、軽度から中等度の潰瘍性大腸炎の治療に広く用いられています。

次に、ステロイド薬が挙げられます。これらは、強力な抗炎症作用を持ち、疾患の急性増悪時に使用されることが一般的です。ステロイド薬は迅速に効果を発揮しますが、長期使用は副作用のリスクが高まるため、必要な期間のみの使用が望ましいとされています。患者の状況に応じて、徐々に減量することが重要です。

また、免疫抑制剤も潰瘍性大腸炎の治療において重要な役割を果たしています。例えば、アザチオプリンや6-メルカプトプリンなどがあります。これらは、免疫系の働きを抑えることによって、炎症を抑制します。特に、ステロイドの効果が不十分な場合や、再発を繰り返す患者に対して用いられます。

さらに、近年注目されているのが生物学的製剤です。これらは、特定の免疫反応をターゲットにした薬剤であり、通常の薬剤では効果が見られない患者に対して使用されます。抗TNF-α抗体（インフリキシマブ、アダリムマブなど）や抗IL-12/23抗体（ウステキヌマブ）がその例です。生物学的製剤は、比較的新しい治療法であり、その効果と安全性に関するデータが蓄積されるにつれて、使用が増加しています。

用途についても触れておく必要があります。潰瘍性大腸炎治療薬は、患者の症状を緩和するだけでなく、病気の進行を抑えることを目的としています。また、患者における再発のリスクを低減し、長期的な寛解を促すことが重要です。患者個々の病態に応じて、最適な治療薬を選択することが、治療成績を向上させる鍵となります。

関連技術としては、治療薬の効果や副作用を評価するためのバイオマーカーの開発が続々と進められています。これにより、個々の患者に最適な治療法を選択し、より効果的な治療を行うことが可能になると期待されています。また、患者の状態をリアルタイムでモニタリングするためのデジタルヘルス技術の導入も進んでおり、患者に対する個別化医療の実現に寄与しています。

最後に、潰瘍性大腸炎の治療においては、医師と患者のコミュニケーションが重要です。患者は自分の症状や治療に関する疑問をしっかりと伝え、医師はそれに対する理解を深めることで最適な治療方針を立てる助けとなります。治療薬は、決して単独で完結するものではなく、生活習慣や食事、ストレス管理といった多角的なアプローチが、病気のコントロールに重要です。

以上のように、潰瘍性大腸炎治療薬は多岐にわたり、それぞれが特有の特徴を持っています。病気を理解し、適切な治療を行うことで、患者さんのQOLを向上させることが可能です。今後も新しい治療法や技術の開発が期待される分野ですので、引き続き注目していく必要があります。


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 潰瘍性大腸炎治療薬の世界市場2022：経口型、注射型(Global Drug for Ulcerative Colitis Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • ソリリス医薬品のグローバル市場2025年：企業・地域・タイプ・用途別分析
  • 避妊薬のグローバル市場2025年：企業・地域・タイプ・用途別分析
  • Tysabri（ナタリズマブ）医薬品のグローバル市場2025年：企業・地域・タイプ・用途別分析
  • ゼルヤンツ(トファチニブ)医薬品のグローバル市場2025年：企業・地域・タイプ・用途別分析
  • レナリドミド医薬品のグローバル市場2025年：企業・地域・タイプ・用途別分析

    • ◆H&Iグローバルリサーチのお客様（例）◆